MyFinsight
Home
Blog
About
Contact
Download
Download image
Initial public
offering, net of issuance...
$269,102K
Exercise of stock options
$11K
Net cash provided by
financing activities
$269,113K
Net increase
(decrease) in cash and cash...
$146,646K
Canceled cashflow
$122,467K
Maturities of marketable
securities
$21,689K
Stock-based compensation
$5,259K
Prepaid expenses and
other current assets
-$4,360K
Non-cash research and
development services
$621K
Other
-$6K
Net cash used in
investing activities
-$101,299K
Net cash used in
operating activities
-$21,168K
Canceled cashflow
$21,689K
Canceled cashflow
$10,246K
Purchases of marketable
securities
$122,988K
Net loss
-$27,232K
Interest receivable on
marketable securities
$1,499K
Accrued expenses
-$1,373K
Accounts payable
-$1,055K
Other long term assets
$174K
Net accretion of
discount/premium on debt...
$73K
Other current
liabilities and lease...
-$8K
Back
Back
Cash Flow
Veradermics, Inc (MANE)
Veradermics, Inc (MANE)
source: myfinsight.com